Michael J Barry1, Richard M Wexler2, Charles D Brackett3, Karen R Sepucha4, Leigh H Simmons4, Bethany S Gerstein2, Vickie L Stringfellow2, Floyd J Fowler2. 1. Informed Medical Decisions Foundation, Boston, Massachusetts. Electronic address: mbarry@imdfoundation.org. 2. Informed Medical Decisions Foundation, Boston, Massachusetts. 3. Dartmouth Institute, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire. 4. Decision Sciences Unit of the General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
INTRODUCTION: Prostate-specific antigen (PSA) testing remains controversial, with most guidelines recommending shared decision making. This study describes men's PSA screening preferences before and after viewing a decision aid and relates these preferences to subsequent clinician visit content. METHODS: Men were recruited from two health systems in 2009-2013. Participants answered a questionnaire before and after decision aid viewing addressing PSA screening preferences and five basic knowledge questions. At one health system, participants also answered a survey after a subsequent clinician visit. Data were analyzed in 2014. RESULTS: One thousand forty-one predominantly white, well-educated men responded to the pre- and post-viewing questionnaire (25% and 29% response rates at the two sites). After viewing, the proportion of patients leaning away from PSA screening increased significantly (p<0.001), with 386 (38%) leaning toward PSA screening versus 436 (43%) before viewing; 174 (17%) unsure versus 319 (32%) before; and 448 (44%) leaning away versus 253 (25%) before. Higher knowledge scores were associated with being more likely to lean against screening and less likely to be unsure (p<0.001). Among 278 men who also completed a questionnaire after a subsequent clinician visit, participants who planned to discuss PSA screening with their clinicians were significantly more likely to report such discussions than participants who did not (148/217 [68%] vs 16/46 [35%], respectively [p<0.001]). CONCLUSIONS: A decision aid reduces men's interest in PSA screening, particularly among the initially unsure. Men who plan to discuss PSA screening with their clinician after a decision aid are more likely to do so.
INTRODUCTION:Prostate-specific antigen (PSA) testing remains controversial, with most guidelines recommending shared decision making. This study describes men's PSA screening preferences before and after viewing a decision aid and relates these preferences to subsequent clinician visit content. METHODS:Men were recruited from two health systems in 2009-2013. Participants answered a questionnaire before and after decision aid viewing addressing PSA screening preferences and five basic knowledge questions. At one health system, participants also answered a survey after a subsequent clinician visit. Data were analyzed in 2014. RESULTS: One thousand forty-one predominantly white, well-educated men responded to the pre- and post-viewing questionnaire (25% and 29% response rates at the two sites). After viewing, the proportion of patients leaning away from PSA screening increased significantly (p<0.001), with 386 (38%) leaning toward PSA screening versus 436 (43%) before viewing; 174 (17%) unsure versus 319 (32%) before; and 448 (44%) leaning away versus 253 (25%) before. Higher knowledge scores were associated with being more likely to lean against screening and less likely to be unsure (p<0.001). Among 278 men who also completed a questionnaire after a subsequent clinician visit, participants who planned to discuss PSA screening with their clinicians were significantly more likely to report such discussions than participants who did not (148/217 [68%] vs 16/46 [35%], respectively [p<0.001]). CONCLUSIONS: A decision aid reduces men's interest in PSA screening, particularly among the initially unsure. Men who plan to discuss PSA screening with their clinician after a decision aid are more likely to do so.
Authors: Søren F Birkeland; Anders K Haakonsson; Susanne S Pedersen; Nina Rottmann; Michael J Barry; Sören Möller Journal: J Med Internet Res Date: 2020-09-02 Impact factor: 5.428
Authors: Sigrid Carlsson; Michael Leapman; Peter Carroll; Fritz Schröder; Peter C Albertsen; Dragan Ilic; Michael Barry; Dominick L Frosch; Andrew Vickers Journal: BMC Med Date: 2015-11-27 Impact factor: 8.775